KKKaren A. Kurdziel

Karen A. Kurdziel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karen A. Kurdziel has a total of 295 co-authors. Here are the top co-authors by number of shared publications:

  • Esther Mena

    Molecular Imaging Program, CCR, NCI, NIH

    15 shared publications
  • Peter L. Choyke

    Molecular Imaging Program, CCR, NCI, NIH

    12 shared publications
  • Stephen Adler

    Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, National Cancer Institute Campus at Frederick, Frederick, MD, USA

    10 shared publications
  • Baris Turkbey

    Molecular Imaging Program, CCR, NCI, NIH

    9 shared publications
  • Peter Choyke

    Molecular Imaging Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA

    8 shared publications
  • Liza Lindenberg

    Molecular Imaging Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA

    7 shared publications

Latest Publications

  • Open Access

    First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging

    by Kurdziel Ka, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, et al.

    OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.


  • Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study

    by Kirsten M Williams, Jennifer Holter-Chakrabarty, Liza Lindenberg, Quyen Duong, Sara K Vesely, Chuong T Nguyen, Joseph P Havlicek, Karen Kurdziel, Juan Gea-Banacloche, Frank I Lin, et al.


  • Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy

    by Frank I. Lin, E. M. Gonzalez, S. Kummar, K. Do, J. Shih, S. Adler, K. A. Kurdziel, A. Ton, B. Turkbey, P. M. Jacobs, et al.

    Background Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-α) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen. Methods Fifteen patients were recruited from a parent therapeutic trial of Z-endoxifen and underwent imaging with 18F-FES PET at baseline. Eight had positive lesions on the baseline scan and underwent follow-up imaging with 18F-FES 1–5 days post administration of Z-endoxifen. Results Statistically significant changes (p = 0.0078) in standard uptake value (SUV)-Max were observed between the baseline and follow-up scans as early as 1 day post drug administration. Conclusion F-FES PET imaging could serve as a pharmacodynamic biomarker for patients treated with ER-directed therapy.


  • Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging

    by Manisha Bhutani, Baris Turkbey, Esther Tan, Neha Korde, Mary Kwok, Elisabet E. Manasanch, Nishant Tageja, Sham Mailankody, Mark Roschewski, Marcia Mulquin, et al.

    The incidence and importance of bone marrow involvement and/or early bone lesions in multiple myeloma (MM) precursor diseases is largely unknown. This study prospectively compared the sensitivity of several imaging modalities in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and MM. Thirty patients (10 each with MGUS, SMM and MM) were evaluated with skeletal survey, [18F]FDG-PET/CT, [18F]NaF-PET/CT and morphologic dynamic contrast enhanced (DCE)-MRI. An additional 16 SMM patients had skeletal surveys and FDG-PET/CT. Among MGUS patients, DCE-MRI found only one focal marrow abnormality; other evaluations were negative. Among 26 SMM patients, five (19%) were re-classified as MM based on lytic bone lesions on CT and six had unifocal or diffuse marrow abnormality. Among MM, marrow abnormalities were observed on FDG-PET/CT in 8/10 patients and on DCE-MRI in nine evaluable patients. Abnormal NaF uptake was observed only in MM patients with lytic lesions on CT, providing no additional clinical information.


  • Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer

    by Andrea B. Apolo, Liza Lindenberg, Joanna H. Shih, Esther Mena, Joseph W. Kim, Jong C. Park, Anna Alikhani, Yolanda Y. McKinney, Juanita Weaver, Baris Turkbey, et al.

    This prospective pilot study evaluated the ability of Na18F PET/CT to detect and monitor bone metastases over time and its correlation with clinical outcomes and survival in advanced prostate cancer. Methods: Sixty prostate cancer patients, including 30 with and 30 without known bone metastases by conventional imaging, underwent Na18F PET/CT at baseline, 6 mo, and 12 mo. Positive lesions were verified on follow-up scans. Changes in SUVs and lesion number were correlated with prostate-specific antigen change, clinical impression, and overall survival. Results: Significant associations included the following: SUV and prostate-specific antigen percentage change at 6 mo (P = 0.014) and 12 mo (P = 0.0005); SUV maximal percentage change from baseline and clinical impression at 6 mo (P = 0.0147) and 6–12 mo (P = 0.0053); SUV change at 6 mo and overall survival (P = 0.018); number of lesions on Na18F PET/CT and clinical impression at baseline (P < 0.0001), 6 mo (P = 0.0078), and 12 mo (P = 0.0029); and number of lesions on Na18F PET/CT per patient at baseline and overall survival (P = 0.017). In an exploratory analysis, paired 99mTc-methylene diphosphonate bone scans (99mTc-BS) were available for 35 patients at baseline, 19 at 6 mo, and 14 at 12 mo (68 scans). Malignant lesions on Na18F PET/CT (n = 57) were classified on 99mTc-BS as malignant 65% of the time, indeterminate 25% of the time, and negative 10% of the time. Additionally, 69% of paired scans showed more lesions on Na18F PET/CT than on 99mTc-BS. Conclusion: The baseline number of malignant lesions and changes in SUV on follow-up Na18F PET/CT significantly correlate with clinical impression and overall survival. Na18F PET/CT detects more bone metastases earlier than 99mTc-BS and enhances detection of new bone disease in high-risk patients.


  • PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study

    by Baris Turkbey, Maria L. Lindenberg, Stephen Adler, Karen A. Kurdziel, Yolanda L. McKinney, Juanita Weaver, Cathy D. Vocke, Miriam Anver, Gennady Bratslavsky, Philip Eclarinal, et al.

    Background Carbonic anhydrase IX (CA-IX) is a potential imaging biomarker of clear cell renal cell carcinoma (ccRCC). Here, we report the results of a phase II clinical trial of a small molecule radiotracer targeting CA-IX (18F-VM4-037) in ccRCC. Methods Between October 2012 and May 2013, 11 patients with kidney masses underwent 18F-VM4-037 PET/CT prior to surgery. Dynamic imaging was performed for the first 45 min post injection and whole-body imaging was obtained at 60 min post injection. Tumors were surgically excised or biopsied within 4 weeks of imaging. Results All patients tolerated the radiotracer well with no adverse events. Ten of the 11 patients had histologically confirmed malignancy. One patient had a Bosniak Type 3 cyst with no tumor found at surgery. Two patients had extrarenal disease and 9 had tumors only in the kidney. Primary ccRCC lesions were difficult to visualize on PET alone due to high uptake of the tracer in the adjacent normal kidney parenchyma, however when viewed in conjunction with CT, the tumors were easily localized. Metastatic lesions were clearly visible on PET. Mean SUV for primary kidney lesions was 2.55 in all patients; in patients with histologically confirmed ccRCC, the mean SUV was 3.16. The time-activity curves (TAC) are consistent with reversible ligand binding with peak activity concentration at 8 min post injection followed by washout. Distribution Volume Ratio (DVR) of the lesions was measured using the Logan graphical analysis method. The mean DVR value across the 9 kidney lesions was 5.2 ± 2.8, (range 0.68–10.34). Conclusion 18F-VM4-037 is a well-tolerated PET agent that allows same day imaging of CA-IX expression. The agent demonstrated moderate signal uptake in primary tumors and excellent visualization of CA-IX positive metastases. While the evaluation of primary ccRCC lesions is challenging due to high background activity in the normal kidney parenchyma, 18F-VM4-037 may be most useful in the evaluation of metastatic ccRCC lesions.


  • Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

    by Neha Korde, Mark Roschewski, Adriana Zingone, Mary Kwok, Elisabet E. Manasanch, Manisha Bhutani, Nishant Tageja, Dickran Kazandjian, Sham Mailankody, Peter Wu, et al.

    Multiple myeloma (MM) is a plasma cell dyscrasia characterized by high levels of clonal heterogeneity in both the asymptomatic (eg, smoldering multiple myeloma [SMM]) and symptomatic phases of the disease.1-5 Clinically, triplet combination therapies are effective in reducing disease burden despite intratumoral clonal heterogeneity.6,7 Recent studies indicate that 3-drug combination regimens using proteasome inhibitors and immunomodulatory drugs yield deep responses in patients with newly diagnosed multiple myeloma (NDMM).8,9 The combination of the selective proteasome inhibitor carfilzomib with lenalidomide and dexamethasone (CRd) was recently given to 392 patients with relapsed MM participating in a phase 3 study, resulting in an unprecedented deep response rate (31.8% complete response [CR] or better) and a median progression-free survival (PFS) of 26.3 months.10 Furthermore, based on a phase 1/2 study that included 52 patients with NDMM, 61% achieved a stringent complete response (sCR) after at least 8 cycles.8 Treatment with CRd was found to have a favorable peripheral neuropathy (PN) profile (all grade: 23%; grade ≥2: 6%), which may allow for greater treatment adherence and an increased likelihood to reach negativity for minimal residual disease (MRD) compared with use of other proteasome inhibitors.8


  • Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?

    by Anna M. Brown, Maria L. Lindenberg, Sandeep Sankineni, Joanna H. Shih, Linda M. Johnson, Suneha Pruthy, Karen A. Kurdziel, Maria J. Merino, Bradford J. Wood, Peter A. Pinto, et al.

    18F-FDG PET/CT is used to characterize many malignancies, but is not recommended for localized prostate cancer. This study explores the value of multi-parametric MRI (mpMRI) in characterizing incidental prostate 18F-FDG uptake.


  • Open Access

    Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging

    by Liza Lindenberg, Anish Thomas, Stephen Adler, Esther Mena, Karen Kurdziel, Julia Maltzman, Bruce Wallin, Kimberly Hoffman, Ira Pastan, Chang Hum Paik, et al.

    Safety and biodistribution of 111 In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging


  • A Pilot Study of the Value of 18F-Fluoro-Deoxy-Thymidine PET/CT in Predicting Viable Lymphoma in Residual 18F-FDG Avid Masses After Completion of Therapy

    by Esther Mena, Maria Liza Lindenberg, Baris I. Turkbey, Joanna Shih, Jean Logan, Stephen Adler, Karen Wong, Wyndham Wilson, Peter L. Choyke, Karen A. Kurdziel

    Background Despite its success in diagnosing and staging lymphoma, 18F-FDG PET/CT can be falsely positive in areas of posttreatment inflammation. 3′-18F-fluoro-3′-deoxy-l-thymidine (18F-FLT) is a structural analog of the DNA constituent thymidine; its uptake correlates with cellular proliferation. This pilot study evaluates the ability of 18F-FLT PET/CT to distinguish viable lymphoma from posttreatment inflammatory changes in 18F-FDG avid residual masses. Methods Twenty-one patients with lymphoma with at least 1 18F-FDG avid residual mass after therapy underwent 18F-FLT PET/CT imaging. 18F-FDG and 18F-FLT uptake values were compared, including quantitative pharmacokinetic parameters extracted from the 18F-FLT time activity curves generated from dynamic data using graphical and nonlinear compartmental modeling. Results The true nature of the residual mass was confirmed by biopsy in 12 patients (8 positive and 4 negative for viable lymphoma and by follow-up CT and/or repeat 18F-FDG PET/CT imaging over 1 year); among the remaining 9 patients, 7 lesions resolved or decreased and 2 showed growth indicative of lymphoma. 18F-FLT PET SUVest.max was significantly higher in tumors than in benign lesions (5.5 [2.2] vs 1.7 [0.6]; P < 0.0001), whereas the difference in 18F-FDG SUVs was not significant (malignant, 7.8 [3.8] vs benign, 5.4 [2.4]; P = 0.11). All of the benign lesions had an 18F-FLT SUVest.max of less than 3.0. Conclusions 18F-FLT shows improved specificity over 18F-FDG in distinguishing residual lymphoma from posttreatment inflammation and may be useful in the evaluation of patients with residual 18F-FDG–positive masses after completing therapy.